Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Therma Bright (THRM) provides an update on its Brazilian performance study of its AcuVid™ COVID-19 Rapid Saliva-Based Antigen Test
  • Therma Bright and its R&D team are now initiating an additional second phase study to optimize AcuVid™
  • It is not making any express or implied claims that its test product has the ability to eliminate or cure COVID-19
  • Therma Bright is a progressive medical device technology company focused on providing consumers and medical professionals with quality medical devices
  • Therma Bright’s (THRM) is down 14.89 per cent and is trading at C$0.40 at close.

Therma Bright’s (THRM) initial phase of the Brazilian study of the AcuVid™ saliva-based rapid antigen test has been completed.

Dr. Ricardo Fujiwara, from the Federal University of Minas Gerais, stated that “The AcuVid™ initial results confirm the sensitivity and specificity results achieved in Therma’s development studies of the AcuVid™ test against the SARS-CoV-2 first identified strain which originated from Wuhan, China.”

Therma Bright and its R&D team are now initiating an additional second phase study to optimize AcuVid™, in collaboration with Safetest Diagnósticos and the University of Minas Gerais substantiate AcuVid™ test’s ability to detect known variants that are currently circulating worldwide.

All viruses – including SARS-CoV-2, the virus that causes COVID-19 – evolve.

When a virus replicates or makes copies of itself, it sometimes changes, which is normal for a virus. These changes are called “mutations”.

A virus with one or more new mutations is referred to as a “variant” of the original virus.

Rob Fia, the CEO, commented, “We are pleased that our Brazil study for our AcuVid™ test confirms the results from our development studies.”

“We will now test AcuVid™ with the known variants to validate its effectiveness and, if necessary, optimize the test to detect these variants,” added Fia.

Therma Bright is not making any express or implied claims that its test product has the ability to eliminate or cure COVID-19 or the SARS-CoV-2 virus.

Therma Bright is a progressive medical device technology company focused on providing consumers and medical professionals with quality medical devices that address their medical and healthcare needs.

Therma Bright’s (THRM) is down 14.89 per cent and is trading at C$0.40 at close.

More From The Market Herald

" BioHarvest Sciences (CSE:BHSC) appoints Steven Lehrer to its advisory board

BioHarvest Sciences (BHSC) has appointed Steven Lehrer as its newest advisory board member, effective immediately.

" CloudMD (TSXV:DOC) Receives U.S. patent approval

CloudMD Software & Services Inc. (DOC) has received US patent approval for its Real Time Intervention Platform.

" NervGen Pharma (TSXV:NGEN) introduces Spinal Cord Injury Board

NervGen Pharma Corp. (NGEN) has introduced its Spinal Cord Injury (SCI) Clinical Advisory Board.
Medicenna Therapeutics Corp - CEO, Fahar Merchant

" Medicenna (TSX:MDNA) receives FDA clearance to expand MDNA11 study

Medicenna Therapeutics (MDNA) has received FDA approval to expand the Phase 1/2 ABILITY study of MDNA11 to clinical trial sites in the US.